Isocucurbitacin B targets STAT3 to induce ferroptosis and promote anti-PD1 immunotherapy responses in breast cancer.

Key Points

• The research aims to explore the effects of isocucurbitacin B on ferroptosis induction and STAT3 inhibition in breast cancer treatment.
• Investigated the dual functionality of isocucurbitacin B in breast cancer cells.
• Analyzed effects on ferroptosis and STAT3 signaling pathways.
• Evaluated the potential for combinatorial immunotherapy strategies.
• Isocucurbitacin B effectively induces ferroptosis in breast cancer cells.
• Inhibition of STAT3 was observed, linking to reduced immune evasion.
• The findings suggest enhanced efficacy of anti-PD1 immunotherapy.